

Registration

Online registration can be accessed at cme.ahn.org:

Click on **Courses**, then scroll down or type in **Highlights of ASH 2023** and click on **Register**.

Fees

Industry: \$500

Physicians: \$125

AHN physicians: \$80

Nursing and others: \$65

AHN Nursing and others: \$45

Residents and fellows: free

Lodging

Fairmont Hotel

510 Market Street

Pittsburgh, PA 15222

To reserve your room at the Fairmont Hotel please click on the link below.



Allegheny General Hospital
Continuing Medical Education
320 East North Avenue
Suite 214, South Tower
Pittsburgh, PA 15212



01/24 Z MX3288469

CME opportunity

Highlights of ASH 2023

Friday, March 1, 2024

Fairmont Hotel
510 Market Street
Pittsburgh, PA 15222

This meeting is not sponsored,
sanctioned by, or part of the
Annual Meeting of the American
Society of Hematology.



Jointly Provided by
Allegheny General Hospital and
Allegheny Health Network Cancer Institute
Division of Hematology and Cellular Therapy
West Penn Hospital

Course overview

The field of hematology has been rapidly evolving. This continuing medical education and nursing continuing professional development education activity will discuss new developments in the diagnosis and treatment of malignant and non-malignant hematological disorders, as presented at the 2023 Annual Meeting of the American Society of Hematology (ASH). At this one-day course, faculty will share the latest updates in myeloid malignancies, lymphoma, leukemia, multiple myeloma, coagulation disorders, and stem cell transplantation. Through presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for hematological malignancies and blood disorders and learn how these new therapies can be integrated into daily practice. This course is intended for primary care physicians, hematologists and medical oncologists, fellows, residents, CRNPs, PAs, nurses, and all other health care providers.

Course objectives/outcomes

- Discuss the cutting-edge data presented at the 2023 Annual Meeting of the American Society of Hematology.
- Identify updates in molecular abnormalities which can be utilized in the diagnosis, prognosis, risk stratification and therapy selection for patients with myeloid malignancies.
- Describe the relevant clinical trial data in clinical practice which has the potential to improve outcomes in patients with malignant hematologic disorders including non-Hodgkin’s lymphoma, CLL, and multiple myeloma.
- Review the updates in sequencing strategies in the era of novel immunotherapies, CAR-T, targeted therapies and stem cell transplantation.
- Discuss the latest advances in coagulation and platelet disorders.

CME accreditation

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Allegheny General Hospital and Allegheny Health Network Cancer Institute West Penn Hospital. Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Allegheny General Hospital designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credits*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Commission on Certification of Physician Assistants (NCCPA) states that the *AMA PRA Category 1 Credits*[™] are acceptable for continuing medical education requirements for recertification.

American Academy of Nurse Practitioners (AANP) accepts *AMA PRA Category 1 Credits*[™] from organizations accredited by the ACCME.

Nursing

West Penn Hospital is approved as a provider of nursing continuing professional development by Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Nursing contact hours pending.

Non-physicians

Allegheny General Hospital certifies participation in this educational activity.

Program agenda

7:15 – 8 a.m.	Registration, breakfast, and visit exhibits
8 – 8:15 a.m.	Welcome and introductions Salman Fazal, MD
8:15 – 9 a.m.	MDS/AML updates Amer Zeidan, MBBS, MHS
9 – 9:45 a.m.	Platelet disorders Shruti Chaturvedi, MBBS, MSCI
9:45 – 10 a.m.	Break and visit exhibits
10 – 10:45 a.m.	Coagulation disorders Peter A. Kouides, MD
10:45 – 11:30 a.m.	Updates in MPN Raajit K. Rampal, MD, PhD
11:30 a.m. – 12:30 p.m.	Lunch and visit exhibits
12:30 – 1:15 p.m.	Multiple myeloma Jack Khouri, MD
1:15 – 2 p.m.	Updates in B-cell lymphoma Medhi Hamadani, MD
2 – 2:45 p.m.	CAR-T therapy Nirav Shah, MD
3 p.m.	Adjournment

Course director



Salman Fazal, MD

Assistant Professor of Medicine,
Drexel University College of Medicine
Director, Cell Transplantation Program
Allegheny Health Network Cancer Institute,
West Penn Hospital

Invited faculty



Shruti Chaturvedi, MBBS, MSCI

Associate Professor of Medicine,
Johns Hopkins University School of Medicine



Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic
Malignancies Program
Memorial Sloan Kettering Cancer Center



Medhi Hamadani, MD

Professor of Medicine, Medical College of Wisconsin
Section Chief, Malignant Hematology
Director BMT and Cellular Therapy Program,
Froedtert Hospital



Nirav Shah, MD

Associate Professor of Medicine,
Lymphoma/BMT program
Medical College of Wisconsin




Jack Khouri, MD

Assistant Professor of Medicine, Cleveland Clinic
Lerner College of Medicine of Case Western
Reserve University



Peter A. Kouides, MD

Professor of Medicine, University of Rochester
School of Medicine and Dentistry
Medical and Research Director, Mary M. Gooley
Hemophilia Treatment Center
Attending Staff Hematologist,
Rochester Regional Health



Amer Zeidan, MBBS, MHS

Associate Professor of Internal Medicine
(Hematology), Section of Hematology,
Department of Internal Medicine,
Yale School of Medicine
Interim Chief, Division of Hematologic Malignancies
Director, Leukemia Program
Assistant Medical Director, Hematology,
Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Leader, Leukemia and Myeloid Malignancies
Clinical Research Team (CRT)
Yale Comprehensive Cancer Center
and Smilow Cancer Hospital

Disclosure of significant relationships with relevant commercial companies. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honorarium, or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).